Table 2 Logistic regression analysis of CRIP1 expression associated with clinical pathological characteristics.
From: CRIP1 inhibits cutaneous melanoma progression through TFAM-mediated mitochondrial biogenesis
Characteristics | Total (N) | OR (95% CI) | P value |
|---|---|---|---|
Pathologic T stage (T4 vs. T1&T2&T3) | 365 | 0.510 (0.334–0.780) | 0.002 |
Pathologic N stage (N1&N2&N3 vs. N0) | 415 | 1.057 (0.717–1.560) | 0.778 |
Pathologic M stage (M1 vs. M0) | 444 | 0.651 (0.286–1.482) | 0.306 |
Pathologic stage (Stage III&Stage IV vs. Stage I&Stage II) | 413 | 1.200 (0.815–1.766) | 0.356 |
Melanoma Clark level (IV&V vs. I&II&III) | 323 | 0.452 (0.280–0.729) | 0.001 |
Melanoma ulceration (Yes vs. No) | 315 | 0.559 (0.357–0.877) | 0.011 |
Tumor tissue site (Trunk vs. Extremities) | 369 | 0.996 (0.661–1.500) | 0.984 |
Breslow depth (> 3 vs. <= 3) | 361 | 0.499 (0.327–0.759) | 0.001 |
Radiation therapy (Yes vs. No) | 465 | 1.565 (0.962–2.545) | 0.071 |
